Stoke Q3 2026 slides: EMPEROR trial advances with zero dropouts
Stoke Therapeutics (STOK) reported Q3 2026 progress, highlighting zero dropouts in its EMPEROR Phase 3 trial for zorevunersen in Dravet syndrome. The company beat revenue estimates but reported a wider-than-expected loss. Stoke has $358.8M in cash, enough to fund operations into early 2028. The trial enrolled 162 patients, exceeding the target, with strong patient retention and statistical significance in endpoints. The FDA has accepted the study's multicomponent approach for regulatory filing.
How this was made
The 30-second read
Why it matters
The update emphasizes trial execution quality (zero discontinuations, strong retention) and a regulatory process positive (FDA accepted the multicomponent endpoint approach), which can improve perceived probability of a successful filing and commercialization readiness.
Market read
Traders may reassess near-term biotech risk as the company highlights pivotal trial execution and an FDA-accepted endpoint framework, both of which can influence probability-weighted outcomes.
What to watch
Cash runway into early 2028 is supportive, but the wider-than-expected loss and the need to fund additional studies (including adult and infant/toddler trials) could temper enthusiasm.
Background
Stoke Therapeutics is advancing zorevunersen for Dravet syndrome in the pivotal EMPEROR Phase 3 trial and is also progressing STK-002 for autosomal dominant optic atrophy.
Ticker impact
Stoke reports EMPEROR Phase 3 progress with 162 enrolled patients and zero treatment discontinuations, plus FDA acceptance of its multicomponent endpoint approach.
Likely upward bias as traders price in improved probability of successful pivotal outcomes and smoother FDA review.
The article provides specific trial execution metrics (zero discontinuations, enrollment above target) and a concrete regulatory signal (FDA accepted the multicomponent approach), both of which are direct catalysts for biotech risk perception.
Market effects
Supports sentiment for intrathecal pediatric rare-disease programs by highlighting retention and endpoint acceptance as key de-risking factors.
Primarily impacts US biotech sentiment and small/mid-cap growth risk appetite.
Limited direct global spillover beyond rare-disease clinical development expectations.
Counterpoint
Despite strong execution and endpoint acceptance, the article does not provide new efficacy results at the primary endpoint, so the market may still wait for the pivotal readout.
Key entities
- companyStoke Therapeutics
NASDAQ-listed biotech advancing zorevunersen in EMPEROR Phase 3 and STK-002 in early development.
- clinical_trialEMPEROR
Stoke’s pivotal Phase 3 trial of zorevunersen in Dravet syndrome, with reported enrollment and retention metrics.
- drugzorevunersen
Lead intrathecal therapy candidate for Dravet syndrome discussed in the update.
- drugSTK-002
Pipeline candidate for autosomal dominant optic atrophy, with Phase 1 OSPREY underway.
- regulatorFDA
Accepted the multicomponent endpoint approach for the U.S. regulatory filing, per management commentary.
